LGL Group (NYSEAMERICAN:LGL) Posts Earnings Results

LGL Group (NYSEAMERICAN:LGL) released its earnings results on Monday. The industrial products company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.09), reports. The firm had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $9.10 million. LGL Group had a net margin of 16.50% and a return on equity of 1.66%.

LGL Group Stock Up 2.2%

Shares of LGL stock traded up $0.15 during mid-day trading on Wednesday, reaching $7.10. 4,462 shares of the company’s stock traded hands, compared to its average volume of 12,501. The company’s 50-day moving average price is $7.14 and its 200-day moving average price is $6.48. The company has a market cap of $46.36 million, a P/E ratio of 64.55 and a beta of 0.31. LGL Group has a 12 month low of $5.45 and a 12 month high of $9.74.

Institutional Investors Weigh In On LGL Group

A hedge fund recently bought a new stake in LGL Group stock. Citadel Advisors LLC purchased a new stake in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned about 0.25% of LGL Group as of its most recent SEC filing. Institutional investors own 30.28% of the company’s stock.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.